Mirati Therapeutics, Inc.
MRTX · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $16 | $14 | $7 | $1 |
| % Growth | 19.8% | 91% | 667.3% | – |
| Cost of Goods Sold | $2 | $1 | $1 | $142 |
| Gross Profit | $14 | $12 | $6 | -$141 |
| % Margin | 84.5% | 90.6% | 88.6% | -15,085.9% |
| R&D Expenses | $115 | $124 | $127 | $141 |
| G&A Expenses | $0 | $0 | $0 | $169 |
| SG&A Expenses | $72 | $75 | $73 | $71 |
| Sales & Mktg Exp. | $0 | $0 | $0 | -$98 |
| Other Operating Expenses | $0 | $0 | $0 | $1 |
| Operating Expenses | $187 | $200 | $200 | $212 |
| Operating Income | -$172 | -$187 | -$194 | -$212 |
| % Margin | -1,049.1% | -1,367.9% | -2,704.4% | -22,668.4% |
| Other Income/Exp. Net | $10 | $10 | $9 | $10 |
| Pre-Tax Income | -$162 | -$177 | -$185 | -$202 |
| Tax Expense | $0 | $0 | -$9 | $0 |
| Net Income | -$162 | -$177 | -$185 | -$202 |
| % Margin | -987.2% | -1,292.3% | -2,575.5% | -21,678.3% |
| EPS | -2.49 | -3.04 | -3.02 | -3.51 |
| % Growth | 18.1% | -0.7% | 14% | – |
| EPS Diluted | -2.49 | -3.04 | -3.02 | -3.51 |
| Weighted Avg Shares Out | 65 | 58 | 58 | 58 |
| Weighted Avg Shares Out Dil | 65 | 58 | 58 | 58 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$171 | -$186 | -$187 | -$208 |
| % Margin | -1,042.3% | -1,359.8% | -2,603.6% | -22,218.7% |